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Abstract
The accumulation of endogenous bile acids contributes to hepatocellular damage during cholestatic liver disease. To examine the
controversy regarding the therapeutic use of ursodeoxycholate (UDCA) in cholestatic patients, we investigated the possible cytoprotection or
synergistic effects of UDCA against chenodeoxycholate (CDCA)-induced injury to isolated rat hepatocytes. Our aim was to investigate the
role of the mitochondrial permeability transition (MPT) in the mechanism of cytotoxicity caused by UDCA plus CDCA. Although not toxic
by itself, UDCA potentiated the mitochondrial depolarization, ATP depletion and cell killing caused by CDCA. Fructose maintained ATP
levels and prevented bile acid-induced cell killing. Cyclosporine A (CyA), a potent inhibitor of the MPT, substantially reduced mitochondrial
depolarization, ATP depletion and cell killing caused by CDCA. Our results demonstrate that the synergistic cytotoxicity by UDCA plus
CDCA is mediated by impairment of mitochondrial function, an event that is expressed via induction of the MPT.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Bile formation is a vital function of the liver and its
impairment is central in the pathogenesis of cholestasis. In
cholestatic disease, intrahepatic accumulation of toxic bile
acids promotes hepatic injury [1]. Although the cellular
mechanisms involved in bile acid-induced injury are still
under investigation, it is known that hydrophobic bile
acids are particularly hepatotoxic. Due to their mem-
brane-active, detergent-like properties, the cytotoxicity of
bile acids has been correlated to the degree of lipophilicity
of the different molecular species [2]. Mechanisms impli-
cated in the toxicity of bile acids include stimulation of
lipid peroxidation [3] and induction of mitochondrial
dysfunction [4–7].
Ursodeoxycholic acid (UDCA) has been used success-
fully in the treatment for primary biliary cirrhosis and
other cholestatic liver diseases in humans [8]. Serum liver
tests and histopathological analyses suggest improvement
of liver function in patients treated with UDCA. In most of
the cases, UDCA shows a favourable effect on biochem-
ical indices [9] but not on symptoms or the progression of
histological damage [10]. Recently we have shown that
UDCA causes synergistic cell killing by toxic bile acids in
rat hepatocyte primary cultures [11]. Likewise, Krahenbuhl
et al. [12] described that UDCA increases the toxicity of
lipophilic bile acids at the level of the mitochondrial
electron transport chain. Conversely, studies made by
others described a putative beneficial effect of UDCA
exerted at the level of mitochondrial function [6,13]. The
aim of the present study was to clarify the mechanisms
involved in the synergistic cell killing by UDCA plus
chenodeoxycholate (CDCA, a lipophilic toxic bile acid)
[1], especially at the level of mitochondrial function.
The results demonstrate that impairment of cellular ATP
generation is a final pathway leading to cell death
after exposure to CDCA, and that the triggering event
is induction of the mitochondrial permeability transition
(MPT).
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2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (Harlan Labs, Madison, WI)
weighing 186F 6 g were maintained in AAALAC-
accredited, climate-controlled facilities and allowed free
access to food (Purina Chow) and water.
2.2. Materials
UDCA and CDCA were purchased from Sigma Chem-
ical Co. (St. Louis, MO). UDCA was dissolved in eth-
anol, CDCA in water. Lactate dehydrogenase (LDH),
commercial kit, was purchased from Sigma and Collage-
nase type 2 was from Worthington (Freehold, NJ). All
other chemicals were of analytical grade and obtained
from standard commercial sources. A Labsystems type
374 plate-reader was used for all measurements of fluo-
rescence intensity.
2.3. Rat hepatocyte isolation and culture
Hepatocytes were isolated according to a modified
procedure of Seglen [14]. Cells were plated on 12-well
plates at a density of 0.6 106 cells per well. Culture
medium was RPMI supplemented with 5% fetal bovine
serum and 15 mM HEPES (pH 7.4). Cells were main-
tained in an incubator at 37 jC, 5% CO2 and humidified
atmosphere. After allowing 2–3 h for the cells to attach,
the medium was replaced with Krebs–Henseleit–HEPES
Buffer (KHH buffer, 119 mM, 4.9 mM KCl, 1.2 mM
KH2PO4, 2.6 mM CaCl2, 1.2 mM MgSO4, 25 mM
NaHCO3, 12.5 mM HEPES, pH 7.4) and bile acids
(150 AM CDCA and/or 250 AM UDCA) were added.
Cells were incubated at 37 jC for 1, 2 or 4 h. In some
experiments, cells were supplemented with 20 mM fruc-
tose or 1 AM CyA.
2.4. Cell viability assay
Cell viability was determined fluorometrically by esti-
mating release of LDH into medium [15]. The determi-
nation of LDH activity is based on the reduction of
pyruvate to lactate as monitored by the decrease in NADH
fluorescence at 450 nm with excitation wavelength 355
nm. Fresh reaction solution was made by mixing 0.4 ml of
16.2 mM pyruvate with 10 ml of 0.2 mM NADH in
phosphate buffer (pH 7.5). After incubation of hepatocytes
with bile acids for 1, 2 or 4 h, 5 Al of the cell-free
supernatant was added to 200 Al of fresh assay solution to
initiate the reaction. Total cellular LDH was determined by
lysing the cells after freezing in a solution of 0.1 M
sodium phosphate buffer (pH 7.0). The amount of LDH
released into the media was expressed as percent of total
LDH.
2.5. Measurement of mitochondrial membrane potential
(Dw) in hepatocytes
To monitor mitochondrial Dw, hepatocytes were loaded
with 6.6 AM tetramethylrhodamine methyl ester (TMRM) in
KHH buffer at room temperature for 10 min. The super-
natant was then aspirated, and the cells returned to the
original volume with KHH. TMRM is a membrane-perme-
able cationic fluorophore that accumulates electrophoreti-
cally in mitochondria in proportion to their Dw [16]. Cell
suspensions (200 Al containing 105 cells) were loaded into
96-well plates and fluorescence measured using excitation
and emission wavelengths of 485 and 590 nm, respectively.
After 5 min of recording basal fluorescence, cells were
incubated with 150 AM CDCA, 250 AM UDCA and/or 1
AM CyA. Mitochondrial Dw was estimated, taking into
account the complete depolarization caused by carbonyl
cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP).
The change in Dw induced by the test agents was expressed
as percent of total Dw.
2.6. Determination of adenine nucleotide content
After incubation of hepatocytes in culture with the
compounds for 1, 2 or 4 h, adenine nucleotide content
was determined by HPLC according to the method of
Jones [17]. The extraction of adenylate nucleotides from
cells was performed as described previously [18]. Quanti-
fication was achieved by employing a standard curve.
2.7. Statistical analysis
Solvent controls (water or ethanol) were included within
each experimental determination and the data is expressed
as a percentage of the respective control (meanF S.E.,
n = 4). Ethanol itself had no effect on any of the three
parameters measured. Statistical significance was deter-
mined by the one-way ANOVA Student–Newman–Keuls
post t test for multiple comparisons. A P value of < 0.05
was considered statistically significant.
3. Results
Addition of CDCA to rat hepatocytes in primary culture
was previously shown to cause a dose-dependent decrease
in cell viability [11]. Furthermore, CDCA’s toxicity was
increased in the presence of UDCA. In the present work,
we have also observed that although nontoxic per se,
UDCA causes synergistic cell killing by CDCA as meas-
ured by LDH leakage (Fig. 1). The control samples
contained the bile acid solvent at adequate concentrations.
Cytotoxicity of CDCA and UDCA plus CDCA was time-
dependent, with cell viability decreasing progressively
throughout the incubation period. After 4 h, cell viability
was only 41F 2% for UDCA plus CDCA compared to a
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63F 2% for CDCA alone. UDCA by itself had no sig-
nificant effect on LDH release. The concentrations used
were determined by taking into account previous data [11],
where we describe the cytotoxicity of bile acids in terms of
dose and time dependence. The concentrations used are
below those that cause detergent-like nonspecific cell kill-
ing.
Incubation of hepatocytes with a toxic dose of CDCA
and UDCA plus CDCA resulted in a decrease of intra-
cellular adenine nucleotide content (Fig. 2), which
appeared to parallel cell death. UDCA at 250 AM had
no effect on cellular ATP levels. It has been shown that
fructose, an alternate carbohydrate source for glycolysis,
protects against cell killing induced by various toxic
compounds [19] and also in hypoxic injury [20]. We
investigated the hypothesis that fructose, by providing an
alternate source of ATP, may prevent bile acid-induced
toxicity. In agreement with previous findings, 20 mM
fructose afforded almost complete protection against ATP
depletion after 4 h of exposure to CDCA or UDCA plus
CDCA (Fig. 2). In addition to preventing ATP depletion,
fructose also protected against UDCA plus CDCA syner-
gistic cytotoxicity (Fig. 3). These results suggest that
inhibition of mitochondrial ATP formation by oxidative
phosphorylation is a key event in the cytotoxicity of bile
acids.
Impairment of mitochondrial function by bile acids may
have drastic consequences on cellular function through the
perturbation of bioenergetic charge and metabolism of the
cell. We next assessed mitochondrial function during expo-
sure of isolated cells to bile acids. Changes of mitochondrial
membrane potential were monitored by the cellular retention
of the fluorescent probe, TMRM.
Similar to the results reported with isolated mitochondria
[7], CDCA addition resulted in a marked, almost complete
decrease of TMRM retention in isolated hepatocytes (Fig.
4). UDCA induced 30% depolarization. CDCA plus UDCA
caused more substantial mitochondrial depolarization when
compared with CDCA alone. CyA inhibited both CDCA-
and UDCA plus CDCA-induced depolarization of mito-
chondrial membrane potential (Fig. 4). Additionally, CyA
Fig. 2. Adenine nucleotide content of hepatocytes following 4-h incubation
in KHH buffer with bile acids (150 AM CDCA and/or 250 AM UDCA). In
some experiments, cells were supplemented with 20 mM fructose or 1 AM
CyA. Adenine nucleotides were determined by HPLC according to the
method of Jones [17]. Using this method, content for control cells was:
AMP, 17F 4 nmol/million cell; ADP, 46F 3 nmol/million cell; ATP,
75F 3 nmol/million cell. Data are expressed as percent content compared
to untreated cells. Data represent the meanF S.E. of measurements from
four separate animals. Values that share the same letter are not statistically
different (P < 0.05).
Fig. 3. Changes in cell viability following 4-h incubation of hepatocytes in
KHH buffer with bile acids (150 AM CDCA and/or 250 AM UDCA). In
some experiments, cells were supplemented with 20 mM fructose or 1 AM
CyA. Cell viability was determined as described in Fig. 1. Data represent
the meanF S.E. of measurements from four separate animals. Values that
share the same letter are not statistically different (P < 0.05).
Fig. 1. Changes in cell viability following incubation of hepatocytes in
KHH buffer with bile acids (150 AM CDCA and/or 250 AM UDCA) for 1,
2 or 4 h. Cell viability was determined fluorometrically by estimating the
release of LDH into media. Total LDH was determined after lysing the
cells; the amount of LDH released into media at any given time during the
incubation was expressed as the percentage of total LDH. Percent viability
was obtained by comparing with control cell viability, considered as 100%
at time 0. Using this method, control cell viability was 89F 6% after 4 h of
incubation. Data represent the meanF S.E. of measurements from four
separate animals.
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also prevented both ATP depletion (Fig. 2) and the asso-
ciated synergistic cell killing (Fig. 3), indicating that bile
acids cytotoxicity is a consequence of impairment of mito-
chondrial function. CyA by itself did not affect mitochon-
drial membrane potential, ATP levels or cell killing (data not
shown).
These observations lead to the hypothesis that CDCA
and the bile acid combination induced the MPTwithin intact
hepatocytes. We should note that bile acids caused an abrupt
leakage of TMRM from mitochondria within as little as 10
min. This preceded the loss of cell viability, which was
significant only after 4 h of incubation (Fig. 1). These
observations indicate that mitochondrial dysfunction pre-
cedes the onset of cell death.
4. Discussion
In patients with cholestatic liver disease, hepatocellular
damage may be aggravated by increased bile acid concen-
trations [1]. At high bile acid concentrations, hepatocellular
damage may reflect the detergent effects of the compounds
leading to direct disruption of cell membranes [21]. Phys-
iological intracellular concentrations of bile acids during
cholestasis have been reported to be f 800 AM [22] and a
similar pattern of hydrophobic bile acids accumulation in
liver and serum of patients has been described [23]. In
most patients, however, such bile acid concentrations do
not correlate with massive hepatocellular injury but with a
progressive cell dysfunction and destruction or loss of
intrahepatic or extrahepatic bile ducts [24]. Therefore,
hepatocellular damage at cholestatic relevant concentra-
tions is likely due to other more specific actions of the
bile acids.
Hydrophobic bile acids, such as CDCA, are implicated to
be major contributors to cholestatic liver diseases. Two
mechanisms of cell death induced by exposure of rat
hepatocytes to toxic bile acids have been described: necrosis
at high concentrations and apoptosis at lower concentrations
[22,25]. Since liver damage in chronic cholestasis is largely
mediated by the effects of high concentrations of retained
bile acids in the liver, we wanted to determine if MPT
induction by bile acids would cause bioenergetic collapse
and cell necrosis, and to examine the role of UDCA in the
process.
At high concentrations, bile acids cause detergent-like
nonspecific disruption of biological membranes. However,
it is important to note that the concentrations of bile acids
achieved in these incubations (150–250 AM) are well within
the range observed in liver from humans and rats with
cholestatic liver disease. Fischer et al. [23] reported that the
levels of bile acids in humans are 215F 39.1 nmol/g liver
(wet weight) in chronic cholestasis. Assuming 100 106
hepatocytes/g wet weight and 5 Al of water/106 hepatocytes
[26], the intracellular concentration of bile acids is estimated
to bef 430 AM. CDCA contributed 41% to total bile acids
and was elevated fourfold [23]. Setchell et al. [24] reported
total bile acid concentrations in human liver tissue as
61.6F 29.7 nmol/g (f 123 AM), comprising mainly CDCA
and cholic acid. Following UDCA or tauroursodeoxycholate
administration [24], higher concentrations and an enrich-
ment in UDCA (30%) at the expense of hydrophobic bile
acids were observed. In a model of experimental cholestasis,
Setchell et al. [24] reported bile acid concentrations in liver
tissue of sham-operated rats as 130.8F 21.3 nmol/g (f 260
AM), and increased seven- to eightfold with bile duct
ligation. Therefore, we contend that the mitochondrial-
specific toxicity observed in these studies is relevant to
what might be observed in vivo, in either rats or humans.
Several reports suggest a beneficial effect of UDCA in
treating cholestatic liver disease [8,27,28], possibly by
competitive antagonism of key cytotoxic responses induced
by hydrophobic bile acids. Serum liver tests and histopatho-
logical studies suggest improvement of liver function in
cholestatic patients treated with UDCA. In most of the
cases, UDCA shows a favourable effect on biochemical
indices [9] but not on the symptoms or the progression of
histological stage [10]. Indeed, the recent report by Neu-
berger [10] draws attention to the necessity to re-examine
the therapeutic benefit of UDCA. Several reports fail to
show cytoprotection by UDCA against toxic bile acids at the
level of mitochondrial function or cell viability [7,11,12,29].
In fact, many reports demonstrate the opposite effect, where
UDCA causes a synergistic killing by CDCA of hepatocytes
in primary culture [11,12].
Because of the importance of mitochondria in cellular
energy metabolism (they provide about 90% of the total
ATP of liver cells), alterations in normal oxidative phos-
phorylation may play an important role in cell pathogenesis.
Indeed, a number of observations suggest that mitochondria
Fig. 4. Mitochondrial depolarization induced by bile acids (150 AM CDCA
and/or 250 AM UDCA). In some experiments, cells were supplemented
with 1 AM CyA. Mitochondrial Dw was measured in cell suspensions as
described in Materials and methods. The change in Dw induced by the test
agents was expressed as percent Dw in the absence of bile acids, taking into
account the complete depolarization of mitochondrial membrane potential
by FCCP. Data represent the meanF S.E. of measurements from four
separate animals. Values that share the same letter are not statistically
different (P < 0.05).
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are a primary target of chemical-induced injury and that
their dysfunction ultimately leads to cell death [30,31]. Both
morphological and biochemical observations support the
concept that bile acids may be cytotoxic by causing mito-
chondrial dysfunction [3–7]. Long-term cholestasis caused
by bile duct ligation is known to lead to impaired hepatic
mitochondrial function in the rat [5], which includes
decreased activities of complexes of the electron transport
chain [5,32], decreased activities of enzymes involved in h-
oxidation [33] and impaired antioxidative defense mecha-
nisms [34,35]. Alterations in hepatic energy metabolism, in
particular glycogen metabolism [36], are also observed.
Enlarged, swollen mitochondria are apparent in histopatho-
logic sections obtained from this model of extrahepatic
cholestasis [4].
In the present work, we confirm and extend previous
findings that mitochondria are an important target of bile
acid toxicity [7,11]. Furthermore, our results demonstrate
that synergistic cell killing by UDCA plus CDCA is
manifested by inhibition of mitochondrial ATP generation.
Consistent with this conclusion is the previous report that
glycochenodeoxycholate, the glycine conjugate of CDCA,
induces lethal hepatocellular injury dependent on ATP
depletion [22]. Fructose, which is an alternate glycolytic
source of cellular ATP, protects against ATP depletion and
cell killing induced by CDCA alone and in combination
with UDCA. Because mitochondria are the primary source
of ATP in liver cells, our results indicate that impairment of
mitochondrial oxidative phosphorylation is an early and
critical event in the mechanism of bile acid cytotoxicity.
Induction of the MPT is widely implicated in the
pathophysiology of cell death caused by a number of
agents [37]. It is characterized by an increase in non-
specific permeability of the inner membrane to low-molec-
ular-weight solutes leading to mitochondrial membrane
depolarization, mitochondrial calcium release, mitochon-
drial swelling and inhibition of oxidative phosphorylation
[38]. The MPT is suggested to reflect the opening of a
pore composed of assorted elements, the formation of
which is inhibited by CyA [39]. Induction of the MPT
likely underlies bile acid-induced mitochondrial uncou-
pling as reflected by the fact that CyA protected against
mitochondrial depolarization, ATP depletion and cell kill-
ing. However, protection by CyA was not complete, which
may reflect the previously reported direct effect of bile
acids on the respiratory chain [7]. It has been shown that
reactive oxygen species are generated by isolated rat
hepatocytes and rat liver mitochondria exposed to hydro-
phobic bile acids [40,41], the impaired electron transport
being responsible for mitochondrial superoxide generation.
Furthermore, oxidative stress or, in general, oxidizing
conditions are inducers of the MPT [38]. Gumpricht et
al. [42] presented evidence that glutathione status of
isolated rat hepatocytes modulates bile acid-induced
necrosis but not apoptosis, which implicates oxidative
stress in the pathogenesis of bile acid-induced necrosis.
In conclusion, our results indicate that UDCA potentiates
the cytotoxicity of CDCA by promoting induction of the
MPT, leading to inhibition of ATP synthesis and metabolic
starvation of the cell. This is consistent with previous
reports describing the potentiation of CDCA-induced mito-
chondrial dysfunction by UDCA [7]. Furthermore, this
research adds to the growing literature that indicates that
UDCA potentiates photodynamic therapy [43] and induces
apoptosis in hepatocellular carcinoma cells [44]. In view of
the wide implication of the MPT in chemical-induced cell
injury, these data draw into question the potential benefit of
prescribing UDCA to treat cholestatic disease. If accumu-
lation of hydrophobic bile acids is indeed a primary factor in
the pathogenesis of cholestatic liver disease, then results
from this study may provide potential new insights regard-
ing the failure of UDCA for preventing the hepatocellular
damage observed clinically in cholestatic liver injury. Induc-
tion of the MPT and subsequent cell injury may represent a
primary pathway for the progressive and continued liver
dysfunction associated with this disease.
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